• Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

In Support of Rare Disease Patients Impacted by COVID-19, NORD Launches Premium and Limited Medical Relief Program

United with more than 25 million Americans living with rare diseases, the National Organization for Rare Disorders (NORD®) today launched its COVID-19 Premium & Medical Relief Program to provide vital support to members of the rare disease community affected by the COVID-19 pandemic. The program will assist those with a confirmed rare disease diagnosis who have been directly impacted by the pandemic through a job loss, reduced work hours, furlough, quarantine, etc.

“COVID-19 poses significant threats to the rare disease community, given the susceptibility of those with chronic conditions and the economic challenges that affect their ability to weather this storm. We are hearing from patients who have been furloughed or laid off and desperately need financial support for insurance, COBRA payments, co-pays and medical expenses,” said Pamela Gavin, Chief Strategy Officer for NORD. “Through this new program, we are providing premium and limited medical assistance to rare patients who need it most during this crisis.”